OBJECTIVES: Recent reports have suggested that @entity1 treated by CAPD have a relatively increased risk of @entity204 compared to @entity1 undergoing @entity2033 , although the cause of this discrepancy is poorly understood. @entity3147 is an important risk factor in @entity454 . Also, @entity535 concentrations, for which the physiological function differs from that of protein, may be an independent risk factor in @entity454 . There is no doubt concerning the prevalence of low @entity535 levels in both @entity2033 and CAPD @entity1 . But the difference in plasma @entity535 levels between these two groups has not been well defined. The purpose of this study is to compare plasma @entity535 levels between @entity1 with @entity454 on @entity2033 and CAPD. METHODS: A cross sectional study of overnight fasting plasma @entity535 concentrations was performed on 12 CAPD and 45 @entity2033 @entity1 with @entity454 , matched by age, sex and body mass index. The levels of individual plasma @entity535 and @entity2796 , EAA, NEAA and @entity18200 were compared for the @entity2033 and CAPD groups. In order to measure losses during @entity2033 and CAPD, @entity535 and protein concentrations were measured from 10 dialysates obtained from 10 @entity2033 @entity1 and 12 peritoneal dialysis solutions from 12 CAPD @entity1 . RESULTS: All of the measured @entity535 concentrations were found to be lower in the CAPD group compared to the @entity2033 group. Furthermore, the levels of @entity2796 (2017.3 +/- 781.1 vs. 903.3 +/- 316.1 mumole/L), EAA(1201.8 +/- 492.6 vs. 567.6 +/- 223.2 mumole/L), NEAA(815.5 +/- 308.6 vs. 335.7 +/- 100.2 mumole/L); and @entity18200 (315.0 +/- 146.0 vs. 145.2 +/- 65.0 mumole/L), were all lower in the CAPD group than in the @entity2033 group. The @entity393 was 2.0 +/- 0.2 g/L in the peritoneal dialysate but was not detectable in the hemodialysates. @entity2796 loss over a one week period was about 61.8 +/- 13.0mmole for the @entity2033 group and 38.0 +/- 13.0 mmole for the CAPD group. CONCLUSIONS: Our results show that @entity535 concentrations are lower in @entity454 @entity1 on CAPD than on @entity2033 . It seems likely that @entity393 in the peritoneal dialysate is a contributing factor to lowered plasma @entity535 concentrations in @entity454 @entity1 on CAPD than on @entity2033 . We believe that the lowered @entity535 concentrations observed in CAPD @entity1 may worsen the clinical outcome compared to @entity2033 @entity1 .

Comparison of plasma @entity535 concentrations in XXXX @entity1 on hemodialysis and peritoneal dialysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2796 :: ('CHEBI:32497', 'Chemical') :: ['TAA'] @entity18200 :: ('51742', 'Gene') :: ['BCAA'] @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD'] @entity3147 :: ('MESH:D044342', 'Disease') :: ['Protein malnutrition'] @entity393 :: ('MESH:D034381', 'Disease') :: ['protein loss'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD']
@entity454 :: (MESH:D007676,Disease) :: ['end-stage renal disease']
